Page last updated: 2024-09-04

levofloxacin and afn 1252

levofloxacin has been researched along with afn 1252 in 1 studies

Compound Research Comparison

Studies (levofloxacin)	Trials (levofloxacin)	Recent Studies (post-2010) (levofloxacin)	Studies (afn 1252)	Trials (afn 1252)	Recent Studies (post-2010) (afn 1252)
4,346	581	2,209	26	5	24

Protein Interaction Comparison

Protein	Taxonomy	levofloxacin (IC50)	afn 1252 (IC50)
Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI	Staphylococcus aureus subsp. aureus MRSA252		0.029

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hafkin, B; Hoban, DJ; Kaplan, N; Karlowsky, JA; Zhanel, GG	1

Other Studies

1 other study(ies) available for levofloxacin and afn 1252

Article	Year
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:8 Topics: Anti-Bacterial Agents; Benzofurans; Enoyl-(Acyl-Carrier-Protein) Reductase (NADH); Enterobacteriaceae; Enterococcus; Microbial Sensitivity Tests; Moraxella catarrhalis; Pyrones; Staphylococcal Infections; Staphylococcus; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus pneumoniae	2009

Article

Year

AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.

Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:8

Topics: Anti-Bacterial Agents; Benzofurans; Enoyl-(Acyl-Carrier-Protein) Reductase (NADH); Enterobacteriaceae; Enterococcus; Microbial Sensitivity Tests; Moraxella catarrhalis; Pyrones; Staphylococcal Infections; Staphylococcus; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus pneumoniae

2009